

available at www.sciencedirect.comjournal homepage: euoncology.europeanurology.com

European Association of Urology



Corrigendum to “Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis” [Eur Urol Oncol 2021;4:927–42]

Ekaterina Laukhina^{a,b,†}, Sung Ryul Shim^{c,†}, Keiichiro Mori^{a,d}, David D'Andrea^a, Francesco Soria^e, Pawel Rajwa^{a,f}, Hadi Mostafaei^{a,g}, Eva Compérat^h, Alessia Cimadamoreⁱ, Marco Moschini^j, Jeremy Yuen-Chun Teoh^k, Dmitry Enikeev^b, Evangelos Xylinas^l, Yair Lotan^m, Juan Palouⁿ, Paolo Gontero^e, Marko Babjuk^{a,o}, J. Alfred Witjes^p, Ashish M. Kamat^q, Morgan Roupret^r, Shahrokh F. Shariat^{a,b,o,s,t,u,*}, Benjamin Pradere^a, European Association of Urology–Young Academic Urologists EAU-YAU Urothelial Carcinoma Working Group

^aDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; ^bInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; ^cDepartment of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea; ^dDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan; ^eDivision of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy; ^fDepartment of Urology, Medical University of Silesia, Zabrze, Poland; ^gResearch Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; ^hDepartment of Pathology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; ⁱSection of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona, Italy; ^jDepartment of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy; ^kS.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China; ^lDepartment of Urology, Bichat-Claude Bernard Hospital, Assistance-Publique-Hôpitaux de Paris, Université de Paris, Paris, France; ^mDepartment of Urology, University of Texas Southwestern, Dallas, TX, USA; ⁿFundació Puigvert, Department of Urology, Autonomous University of Barcelona, Barcelona, Spain; ^oDepartment of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic; ^pDepartment of Urology, Radboud University, Nijmegen Heyendaal, the Netherlands; ^qDepartment of Urology, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA; ^rUrology, GRC n°5, Predictive Onco-Urology, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France; ^sKarl Landsteiner Institute of Urology and Andrology, Vienna, Austria; ^tDepartment of Urology, Weill Cornell Medical College, New York, NY, USA; ^uDepartment of Urology, University of Texas Southwestern, Dallas, TX, USA

The original article contained some typographic errors. The authors apologize for any inconvenience and report the correct results here.

In Table 1, the data for Bladder EpiCheck in the study by Pierconti (2021) should be sensitivity of 94% and specificity of 79% for high-grade (HG) disease.

Corrections have been made to pooled values for the Bladder EpiCheck HG analysis in Supplementary Table 1 and the Supplementary figures.

In Section 3.2.2., corrected results for Bladder EpiCheck are as follows. The pooled sensitivity, specificity, positive predictive value, and negative predictive value were 0.91 (95% CI 0.85–0.97), 0.81 (95% CI 0.78–0.85), 0.43 (95% CI 0.18–0.67), and 0.98 (95% CI 0.96–0.99), respectively. The pooled diagnostic odds ratio was 36.47 (95% CI 17.72–75.04).

[†] These authors contributed equally.

* Corresponding author. Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, Austria. Tel. +43 1404 0026 150; Fax: +43 1404 0023 320.

E-mail address: shahrokh.shariat@meduniwien.ac.at (S.F. Shariat).



Conflicts of interest: Ekaterina Laukhtina is supported by the EUSP Scholarship of the European Association of Urology (EAU). Keiichiro Mori is supported by The Uehara Memorial Foundation.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.euo.2022.01.003>.